Cargando…
Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease
BACKGROUND: Sodium–glucose cotransporter-2 (SGLT2) inhibitors are cardioprotective agents in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease (CVD). Since little is known about their uptake in atherosclerotic CVD, we examined SGLT2 inhibitor prescribing trends and id...
Autores principales: | Ozaki, Aya F., Ko, Dennis T., Chong, Alice, Fang, Jiming, Atzema, Clare L., Austin, Peter C., Stukel, Therese A., Tu, Karen, Udell, Jacob A., Naimark, David, Booth, Gillian L., Jackevicius, Cynthia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270657/ https://www.ncbi.nlm.nih.gov/pubmed/37311594 http://dx.doi.org/10.9778/cmajo.20220039 |
Ejemplares similares
-
Prescribing Patterns for Sodium-Glucose Cotransporter 2 Inhibitors: A Survey of Nephrologists
por: Singh, Tripti, et al.
Publicado: (2023) -
Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants
por: Shurrab, Mohammed, et al.
Publicado: (2021) -
Effect of electronic prescribing with formulary decision support on medication tier, copayments, and adherence
por: Pevnick, Joshua M, et al.
Publicado: (2014) -
Factors associated with door-in to door-out delays among ST-segment elevation myocardial infarction (STEMI) patients transferred for primary percutaneous coronary intervention: a population-based cohort study in Ontario, Canada
por: Shi, Oumin, et al.
Publicado: (2018) -
Hospital‐Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome
por: Ozaki, Aya F., et al.
Publicado: (2022)